IL181169A0 - Trifluoromethyl substituted benzamides as kinase inhibitors - Google Patents

Trifluoromethyl substituted benzamides as kinase inhibitors

Info

Publication number
IL181169A0
IL181169A0 IL181169A IL18116907A IL181169A0 IL 181169 A0 IL181169 A0 IL 181169A0 IL 181169 A IL181169 A IL 181169A IL 18116907 A IL18116907 A IL 18116907A IL 181169 A0 IL181169 A0 IL 181169A0
Authority
IL
Israel
Prior art keywords
kinase inhibitors
substituted benzamides
trifluoromethyl substituted
trifluoromethyl
benzamides
Prior art date
Application number
IL181169A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL181169A0 publication Critical patent/IL181169A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL181169A 2004-08-11 2007-02-05 Trifluoromethyl substituted benzamides as kinase inhibitors IL181169A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417905.7A GB0417905D0 (en) 2004-08-11 2004-08-11 Organic compounds
PCT/EP2005/008695 WO2006015859A1 (en) 2004-08-11 2005-08-10 Trifluoromethyl substituted benzamides as kinase inhibitors

Publications (1)

Publication Number Publication Date
IL181169A0 true IL181169A0 (en) 2007-07-04

Family

ID=33017336

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181169A IL181169A0 (en) 2004-08-11 2007-02-05 Trifluoromethyl substituted benzamides as kinase inhibitors

Country Status (17)

Country Link
US (2) US20080096883A1 (enExample)
EP (1) EP1778640A1 (enExample)
JP (1) JP2008509187A (enExample)
KR (1) KR20070046851A (enExample)
CN (2) CN101039914A (enExample)
AU (1) AU2005270313A1 (enExample)
BR (1) BRPI0514288A (enExample)
CA (1) CA2575316A1 (enExample)
EC (1) ECSP077235A (enExample)
GB (1) GB0417905D0 (enExample)
IL (1) IL181169A0 (enExample)
MA (1) MA28822B1 (enExample)
MX (1) MX2007001642A (enExample)
NO (1) NO20071300L (enExample)
RU (1) RU2007108861A (enExample)
TN (1) TNSN07048A1 (enExample)
WO (1) WO2006015859A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) † 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
EP1878727A4 (en) * 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
RU2452492C2 (ru) * 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
AU2007272533A1 (en) * 2006-07-13 2008-01-17 Novartis Ag Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
AU2007293065B2 (en) * 2006-09-05 2011-08-18 Amgen Inc. Phthalazine, AZA- and diaza-phthalazine compounds and methods of use
US20100173426A1 (en) * 2006-12-19 2010-07-08 Johnson Faye M Biomaker identifying the reactivation of stat3 after src inhibition
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
US8022085B2 (en) * 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
AU2008248073B2 (en) * 2007-05-07 2011-03-24 Amgen Inc. Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
US20100292292A1 (en) * 2007-09-13 2010-11-18 Link Medicine Corporation Treatment of Neurodegenerative Diseases Using Indatraline Analogs
US8367671B2 (en) * 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
US20110039845A1 (en) 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
WO2010025201A1 (en) 2008-08-29 2010-03-04 Amgen Inc. Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases.
WO2010025202A1 (en) 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
US8772481B2 (en) 2008-10-10 2014-07-08 Amgen Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
CN102316738A (zh) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 作为激酶抑制剂的酰胺类
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
CA2765030C (en) 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
WO2010144586A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
PH12012500809A1 (en) * 2009-10-30 2012-11-26 Ariad Pharma Inc Methods and compositions for treating cancer
CN102675289B (zh) * 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
EP2701507A1 (en) * 2011-04-26 2014-03-05 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
SG11201606876RA (en) 2015-03-04 2016-10-28 Gilead Sciences Inc Toll like receptor modulator compounds
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN111904960A (zh) * 2020-05-19 2020-11-10 合肥合源药业有限公司 一种固体分散体及药用组合物
KR102463217B1 (ko) * 2020-07-13 2022-11-07 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111925331A (zh) * 2020-07-14 2020-11-13 上海毕得医药科技有限公司 一种6-溴酞嗪的合成方法
CN122167728A (zh) * 2026-05-08 2026-06-09 苏州先觉生物科技有限公司 一种胶原拟肽及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587829B1 (en) * 1997-07-31 2003-07-01 Schering Corporation Method and apparatus for improving patient compliance with prescriptions
US6523009B1 (en) * 1999-11-06 2003-02-18 Bobbi L. Wilkins Individualized patient electronic medical records system
US20030236682A1 (en) * 1999-11-08 2003-12-25 Heyer Charlette L. Method and system for managing a healthcare network
US6684276B2 (en) * 2001-03-28 2004-01-27 Thomas M. Walker Patient encounter electronic medical record system, method, and computer product
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
RU2007108861A (ru) 2008-09-20
NO20071300L (no) 2007-04-19
WO2006015859A1 (en) 2006-02-16
US20060035897A1 (en) 2006-02-16
BRPI0514288A (pt) 2008-06-10
MX2007001642A (es) 2007-04-10
GB0417905D0 (en) 2004-09-15
CA2575316A1 (en) 2006-02-16
KR20070046851A (ko) 2007-05-03
ECSP077235A (es) 2007-03-29
CN101039914A (zh) 2007-09-19
AU2005270313A1 (en) 2006-02-16
JP2008509187A (ja) 2008-03-27
EP1778640A1 (en) 2007-05-02
MA28822B1 (fr) 2007-08-01
TNSN07048A1 (en) 2008-06-02
CN101696188A (zh) 2010-04-21
US20080096883A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
MA28822B1 (fr) Benzamides substitues trifluoromethyle comme inhibiteurs de kinase
IL181811A (en) Phenylaminopyrimidines are conserved in trifluoromethyl as inhibitors of @ - @ abl - @ bcr @@ kinase
IL181720A0 (en) Bicyclic amides as kinase inhibitors
EP1794137A4 (en) SPECIFIC KINASE INHIBITORS
EP1753428A4 (en) INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
GB2424882B (en) Selective kinase inhibitors
GB0403635D0 (en) Pyridinocarboxamides with improved activity as kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL183276A0 (en) Kinase inhibitors
IL179280A0 (en) Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
EP1761268A4 (en) KINASE INHIBITORS BASED ON PYRROLOTRIAZINE
ZA200608221B (en) Thiadlazolidinones as GSK-3 Inhibitors
IL190078A0 (en) Kinase inhibitors
ZA200606152B (en) 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
EP1773837A4 (en) Pyrrolotriazine KINASE INHIBITORS
PL1943243T3 (pl) Inhibitory kinazy
EP1713793A4 (en) PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
ZA200607648B (en) Kinase inhibitors
ZA200608775B (en) Monocyclic heterocycles as kinase inhibitors
ZA200700650B (en) Bicyclic amides as kinase inhibitors
PL1896422T3 (pl) Inhibitory kinazy tyrozynowej
EP1789055A4 (en) INHIBITORS OF THIAZOLOPYRIDINE KINASE
HK1101689A (en) Trifluoromethyl substituted benzamides as kinase inhibitors